4.6 Article

A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice

期刊

CELL REPORTS MEDICINE
卷 2, 期 8, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.xcrm.2021.100372

关键词

-

资金

  1. NIH [AI122070]
  2. Houston Methodist Academy of Medicine

向作者/读者索取更多资源

Despite partial protection provided by the BCG vaccine, tuberculosis remains a leading cause of infectious disease death, claiming approximately 1.5 million lives annually. The development of mucosal vaccines expressing autophagy-inducing peptide C5 and mycobacterial Ag85B-p25 epitope using replication-defective human adenovirus (HAdv(85C5)) and bovine adenovirus (BAdv(85C5)) vectors showed promising results in protecting mice against tuberculosis, with enhanced antigen presentation and robust T cell expansion. BAdv(85C5) demonstrated significant reductions in Mycobacterium tuberculosis lung burden in BCG-vaccinated mice, highlighting its potential as a mucosal vaccine for tuberculosis.
Although the BCG vaccine offers partial protection, tuberculosis remains a leading cause of infectious disease death, killing similar to 1.5 million people annually. We developed mucosal vaccines expressing the autophagy-inducing peptide C5 and mycobacterial Ag85B-p25 epitope using replication-defective human adenovirus (HAdv(85C5)) and bovine adenovirus (BAdv(85C5)) vectors. BAdv(85C5)-infected dendritic cells (DCs) expressed a robust transcriptome of genes regulating antigen processing compared to HAdv(85C5)-infected DCs. BAdv(85C5)-infected DCs showed enhanced galectin-3/8 and autophagy-dependent in vitro Ag85B-p25 epitope presentation to CD4 T cells. BCG-vaccinated mice were intranasally boosted using HAdv(85C5) or BAdv(85C5) followed by infection using aerosolized Mycobacterium tuberculosis (Mtb). BAdv(85C5) protected mice against tuberculosis both as a booster after BCG vaccine (>1.4-log(10) reduction in Mtb lung burden) and as a single intranasal dose (>0.5-log(10) reduction). Protection was associated with robust CD4 and CD8 effector (T-EM), central memory (T-CM), and CD103(+)/CD69(+) lung-resident memory (T-RM) T cell expansion, revealing BAdv(85C5) as a promising mucosal vaccine for tuberculosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据